Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00107536 | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT02426450 | RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC | unknown | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2015 | clinicaltrials |
| NCT02418988 | Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 120 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00006016 | Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01003015 | Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 36 | BayerINDUSTRY | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00056992 | Testing of ADI-PEG in Hepatocellular Carcinoma | completed | Phase 2 | 34 | FDA Office of Orphan Products DevelopmentFED | 1 | Mar 25, 2015 | clinicaltrials |
| NCT02290977 | Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Dec 5, 2014 | clinicaltrials |
| NCT02070419 | TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 2, 2014 | clinicaltrials |
| NCT02242786 | Diffusion-Weighted Magnetic Resonance Imaging | unknown | Phase 2 | 17 | Samsung Medical CenterOTHER | 1 | Nov 7, 2014 | clinicaltrials |
| NCT00108953 | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 96 | BayerINDUSTRY | 6 | Oct 31, 2014 | clinicaltrials |
| NCT00083226 | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00808145 | Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Lahey ClinicOTHER | 1 | Oct 22, 2014 | clinicaltrials |
| NCT00627042 | Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy | completed | Phase 2 | 42 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 8, 2014 | clinicaltrials |
| NCT02240771 | Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 124 | All India Institute of Medical SciencesOTHER | 1 | Sep 16, 2014 | clinicaltrials |
| NCT02202564 | Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 81 | Huazhong University of Science and TechnologyOTHER | 0 | Jul 29, 2014 | clinicaltrials |
| NCT01722175 | Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer(ALPPS) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 22, 2014 | clinicaltrials |
| NCT01669668 | Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 16, 2014 | clinicaltrials |
| NCT01432314 | Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)(RTANDTACE) | withdrawn | Phase 2 | 0 | Asan Medical CenterOTHER | 0 | Jun 26, 2014 | clinicaltrials |
| NCT00484211 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 40 | AGC Biologics S.p.A.INDUSTRY | 1 | May 30, 2014 | clinicaltrials |
| NCT00604721 | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT02018757 | Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC(SEATH) | unknown | Phase 2 | 250 | First Hospital of China Medical UniversityOTHER | 1 | May 28, 2014 | clinicaltrials |
| NCT00639509 | IMC-A12 in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00493428 | Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study | withdrawn | Phase 2 | 0 | University of ManitobaOTHER | 1 | May 16, 2014 | clinicaltrials |
| NCT00023946 | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00044512 | A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma | completed | Phase 2 | 137 | BayerINDUSTRY | 5 | Apr 16, 2014 | clinicaltrials |
| NCT00142428 | Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00142467 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00361309 | SU011248 in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 24 | University of British ColumbiaOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01215565 | Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma(Fibrolam) | terminated | Phase 2 | 4 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00943449 | 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma(Shelter) | completed | Phase 2 | 57 | 4SC AGINDUSTRY | 2 | Jan 16, 2014 | clinicaltrials |
| NCT01128803 | Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response | terminated | Phase 1 / Phase 2 | 1 | Nantes University HospitalOTHER | 1 | Nov 7, 2013 | clinicaltrials |
| NCT01204177 | Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.(BASIL) | completed | Phase 2 | 70 | BayerINDUSTRY | 4 | Sep 6, 2013 | clinicaltrials |
| NCT01934829 | Urea Cream Treatment Sorafenib-Associated HSFR in HCC | completed | Phase 2 | 871 | Chinese Anti-Cancer AssociationOTHER | 1 | Sep 4, 2013 | clinicaltrials |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 14 | Proacta, IncorporatedINDUSTRY | 4 | Aug 23, 2013 | clinicaltrials |
| NCT00052364 | Oxaliplatin in Treating Patients With Liver Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00238394 | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT01861912 | Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma(ACTION) | unknown | Phase 2 / Phase 3 | 258 | Guangdong Provincial People's HospitalOTHER | 0 | Jun 5, 2013 | clinicaltrials |
| NCT00033462 | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01858207 | Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | unknown | Phase 2 | 60 | Shi-Ming LinOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00242502 | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT01821482 | A Study of DC-CIK to Treat Hepatocellular Carcinoma | unknown | Phase 2 | 100 | Guangxi Medical UniversityOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003 | terminated | Phase 2 | 73 | Auron Healthcare GmbHINDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | completed | Phase 2 | 107 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 5 | Feb 28, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2015source: clinicaltrials